Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia

NCT01314274 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT01314274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01314274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
June 30, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epistaxis, hht, morbus osler